PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.02%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.67%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
1.81%
Gross profit growth of 1.81% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
2.13%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
6.86%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
1.99%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
2.00%
Positive EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
2.00%
Positive diluted EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.95%
10Y CAGR of 70.95% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
66.15%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 13.03%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
36.76%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 2.18%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
212.66%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 9.25% over a decade. Joel Greenblatt might see a standout compounder of earnings.
73.93%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 25.82%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
37.10%
3Y net income/share CAGR of 37.10% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
219.61%
Equity/share CAGR of 219.61% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
131.65%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 32.48%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
64.76%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.28%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.71%
AR growth of 77.71% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
1.23%
Inventory growth far above Medical - Pharmaceuticals median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
2.13%
Asset growth of 2.13% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
2.84%
BV/share growth of 2.84% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
57.98%
Debt growth of 57.98% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
0.69%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.